乳腺癌胃肠道转移诊疗进展

摘要

骨、肝脏、肺及中枢神经系统是乳腺癌远处转移最常累及的靶器官, 胃肠道转移(gastrointestinal metastasis, GIM)发生率偏低但预后极差, 属于特殊转移亚型. 临床数据显示其总体发生率约3%-8%, 尸检检出率可达15%-25%, 其中乳腺浸润性小叶癌占70%-90%, 与浸润性导管癌差异显著. GIM临床表现隐匿、症状缺乏特异性, 内镜与影像学表现易与原发性胃肠道肿瘤混淆, 首诊误诊率超过50%, 易导致治疗方向偏差并延误最佳干预时机. 近年来, 随着分子病理诊断技术普及、新一代抗体药物偶联物陆续上市, 联合靶向、内分泌及免疫治疗的精准诊疗理念不断迭代, GIM诊疗已由传统姑息化疗转向以分子分型为核心的个体化综合治疗, 患者生存结局与生活质量显著改善. 本文基于近5年PubMed、EMBASE、Cochrane Library、SABCS、ESMO、ASCO、CSCO等权威数据库及最新指南, 系统梳理GIM流行病学特征、临床与病理特点、诊断路径、全身治疗、局部干预及预后相关因素, 总结该领域内关键进展与现存问题, 旨在为临床规范化诊疗及后续研究提供循证依据.

关键词: 乳腺肿瘤; 胃肠道转移; 浸润性小叶癌; 分子分型; 抗体药物偶联物; 精准诊疗; 靶向治疗

核心提要: 乳腺癌胃肠道转移是一类预后不良的特殊转移亚型, 在浸润性小叶癌中高发; 该病临床表现隐匿、易与原发性胃肠道肿瘤混淆, 结合分子病理联合多模态影像学检查可实现精准鉴别; 以新一代抗体药物偶联物为核心、联合靶向、内分泌、免疫的个体化综合方案, 可有效改善患者生存状态与生活质量; 目前该领域仍存在诊断延误、高级别循证证据不足、急症处理方案不统一等临床瓶颈, 亟需建立标准化诊疗路径并推广多学科协作诊疗模式.

Advances in diagnosis and treatment of gastrointestinal metastases from breast cancer

Xiang-Xin Zheng, Sai Zhou, Peng Yang, Chao Huang, Zhi-Feng Chen, Nan-Gan Xu, Ming-Ming Tian, Xiao-Chao Zhu, Xiao-Qing Guan

Xiang-Xin Zheng, Peng Yang, Chao Huang, Zhi-Feng Chen, Nan-Gan Xu, Ming-Ming Tian, Xiao-Chao Zhu, Xiao-Qing Guan, Department of Thyroid and Breast Surgery, Jiangsu Province (Suqian) Hospital/The Suqian Clinical College of Xuzhou Medical University, Suqian 223800, Jiangsu Province, China

Sai Zhou, Department of Infection Management, Jiangsu Province (Suqian) Hospital/The Suqian Clinical College of Xuzhou Medical University, Suqian 223800, Jiangsu Province, China

Supported by: Special Research Project of The First People's Hospital of Suqian City, Jiangsu Province, No. KY202315.

Corresponding author: Xiao-Qing Guan, Professor, Chief Physician, Department of Thyroid and Breast Surgery, Jiangsu Province (Suqian) Hospital/The Suqian Clinical College of Xuzhou Medical University, No. 120 Suzhi Road, Suqian 223800, Jiangsu Province, China. guan_dr@163.com

Received: May 6, 2026
Revised: June 11, 2026
Accepted: July 2, 2026
Published online: July 28, 2026

Abstract

The bone, liver, lung, and central nervous system are the most common sites of distant metastasis in breast cancer. Gastrointestinal metastasis (GIM) represents a rare but distinctive metastatic subtype, characterized by a low incidence yet an extremely poor prognosis. Clinical data indicate an overall incidence of approximately 3%-8%, with autopsy detection rates reaching 15%-25%. Notably, invasive lobular carcinoma accounts for 70%-90% of GIM cases, highlighting a marked difference from invasive ductal carcinoma. GIM presents with insidious clinical manifestations and non-specific symptoms, and its endoscopic and imaging features are frequently indistinguishable from those of primary gastrointestinal tumors. The misdiagnosis rate at initial diagnosis exceeds 50%, often leading to inappropriate treatment and delayed optimal intervention. In recent years, with the widespread adoption of molecular pathological diagnostic techniques and the introduction of next-generation antibody-drug conjugates, the paradigm of precise diagnosis and treatment integrating targeted, endocrine, and immunotherapy has continued to evolve. GIM management has transitioned from traditional palliative chemotherapy to individualized comprehensive therapy guided by molecular subtyping, substantially improving both survival outcomes and quality of life in affected patients. Based on a systematic review of authoritative databases including PubMed, EMBASE, and the Cochrane Library, as well as major international conference proceedings (SABCS, ESMO, ASCO, and CSCO) and the latest guidelines published over the past five years, this article systematically reviews the epidemiological characteristics, clinicopathological features, diagnostic approaches, systemic therapies, local interventions, and prognostic factors of GIM. We summarize key advances and existing challenges in this field, with the aim of providing evidence-based references to inform standardized clinical practice and guide future research directions.

Key Words: Breast cancer; Gastrointestinal metastasis; Invasive lobular carcinoma; Molecular typing; Antibodydrug conjugate; Precise diagnosis and treatment; Targeted therapy

核心提要: 乳腺癌胃肠道转移是一类预后不良的特殊转移亚型, 在浸润性小叶癌中高发; 该病临床表现隐匿、易与原发性胃肠道肿瘤混淆, 结合分子病理联合多模态影像学检查可实现精准鉴别; 以新一代抗体药物偶联物为核心、联合靶向、内分泌、免疫的个体化综合方案, 可有效改善患者生存状态与生活质量; 目前该领域仍存在诊断延误、高级别循证证据不足、急症处理方案不统一等临床瓶颈, 亟需建立标准化诊疗路径并推广多学科协作诊疗模式.

---

0 引言

乳腺癌位居全球女性恶性肿瘤发病首位, 晚期复发及远处转移是导致患者死亡的首要因素[1,2]. 既往临床普遍认为乳腺癌胃肠道转移属于罕见转移类型, 随着内镜普及、病理鉴别技术提升, 临床确诊胃肠道转移(gastrointestinal metastasis, GIM)的病例数逐年增多. 相较于骨、肝、肺等常见转移灶, GIM好发于乳腺浸润性小叶癌(invasive lobular carcinoma, ILC), 肿瘤细胞侵袭模式特殊、复发间隔时间长、临床症状隐匿, 误诊问题突出[3-5]. 伴随分子分型体系完善与新一代抗体药物偶联物(antibody-drug conjugate, ADC)、靶向、免疫新药投入临床, GIM治疗模式发生了重大变革. 但目前国内外尚无针对GIM的专属诊疗指南, 外科手术指征界定模糊、急症处置方案缺乏统一标准, 加之多学科间认知不足, 跨学科误诊现象较为常见. 基于上述临床现状, 本文整合近5年国内外循证医学数据, 对乳腺癌胃肠道转移诊疗进展进行系统性综述.

1 流行病学与生物学特征

1.1 发生率与人群分布

乳腺癌胃肠道转移临床整体发生率约3%-8%, 尸检检出率可达15%-25%, 提示大量无症状患者生前未能明确诊断, 漏诊问题突出[6-9]. ILC发生胃肠道转移风险为浸润性导管癌的5-8倍[10-12], 70%-90%的GIM来源于ILC[13-16]. 转移部位以胃最多见(60%-70%)[17-19], 其次为结直肠(20%-30%)[20,21]、小肠(5%-10%)[22,23]、食管(1%-3%)[24]. 自乳腺癌原发灶确诊至发生胃肠道转移的中位间隔时间为6.5年, 最长可达33年, 提示该类患者需长期随访监测. 患病群体以50-70岁绝经后女性居多, 原发肿瘤多为Ⅱ-Ⅲ期, 常合并腋窝淋巴结转移, 侵袭性较强[25,26].

1.2 分子生物学机制

ILC高发胃肠道转移的核心分子机制为CDH1(E-cadherin)基因失活或表达缺失, 细胞间黏附能力下降, 肿瘤细胞呈单细胞离散式沿消化道黏膜下层浸润播散. 近年研究进一步明确相关调控通路[27]: (1)CDH1缺失可激活Wnt/β-catenin通路, 增强肿瘤细胞的迁移与侵袭能力; (2)肿瘤高表达CXCR4、CCR9趋化因子受体, 介导肿瘤向消化道定向转移; (3)肿瘤易出现印戒细胞分化, 病理形态与原发胃印戒细胞癌高度相似, 是临床误诊的重要诱因[28]; (4)分子亚型以HR+/HER2-为主, 占65%-75%, HER2阳性占10%-15%, 三阴性约占10%-20%.

1.3 临床症状

GIM临床表现无特异性, 极易与原发消化道疾病混淆: (1)胃转移: 上腹隐痛、腹胀纳差、呕吐、消化道出血、体重骤降, 弥漫浸润型可形成皮革胃; (2)结直肠转移: 腹痛腹泻、便血、肠梗阻、腹部包块; (3)小肠转移: 反复肠套叠、肠穿孔、活动性出血; (4)全身表现: 消瘦、难治性贫血、低蛋白血症、腹水、电解质紊乱. 约20%-30%患者以消化道不适作为乳腺癌术后首发复发症状, 首诊多就诊于消化内科, 易被误诊为原发胃肠恶性肿瘤[29-31].

2 诊断与鉴别诊断

乳腺癌GIM诊断核心是溯源定性, 明确肿瘤来源于乳腺而非胃肠道原发. 诊断流程遵循: 影像学初筛-内镜活检-病理确诊-分子分型检测.

2.1 影像学评估

腹部增强CT为首选筛查手段, 典型征象: 胃壁弥漫性增厚(>10 mm)、均匀强化、无明显局限性肿块; 结直肠壁环形增厚、管腔狭窄; 肠系膜浸润、腹膜结节、腹水. 腹部增强核磁共振成像对小肠、直肠转移及腹膜受累的检出敏感度更高. PET-CT被ESMO、CSCO 2025指南Ⅰ级推荐, 用于全身分期、隐匿转移检出及疗效评估, 可将病灶检出率提升20%-30%.

2.2 内镜与活检

胃镜联合结肠镜为确诊金标准[32,33]. 胃转移可见黏膜充血水肿、糜烂、结节样隆起, 弥漫浸润者胃壁僵硬、蠕动消失; 结直肠转移可见黏膜下隆起、环形狭窄、溃疡. 活检关键要点: 必须多点深挖活检, 仅取材表面黏膜易造成假阴性结果.

2.3 病理与免疫组化鉴别诊断

免疫组化是判定肿瘤组织来源的核心依据. 乳腺来源病灶典型表现为GATA3(+)、Mammaglobin(+)、CK7(+)、CK20(-)、CDX2(-)、Villin(-); 原发性胃肠道肿瘤标志物表达与之相反,见表1. 确诊乳腺来源后, 必须常规检测ER、PR、HER2、Ki67; HER2(2+)需进一步行荧光原位杂交或显色原位杂交验证; 必要时补充检测PIK3CA、BRCA1/2、程序性死亡配体-1(programmed death ligand-1, PD-L1)等分子标记物[34,35]. 临床严禁在未明确肿瘤组织来源前, 按照原发性胃肠道肿瘤开展根治性手术及辅助化疗; 仅当患者出现危及生命的大出血、穿孔、完全性肠梗阻等急症时, 可考虑姑息性、挽救性手术.

表1 乳腺癌胃肠道转移与原发性胃肠道肿瘤免疫组化鉴别要点.

标志物	乳腺癌胃肠道转移	原发性胃癌/结直肠癌
GATA3	+(80%-90%)	-
Mammaglobin	+(50%-70%)	-
CK7	+	-
CK20	-	+
CDX2	-	+
Villin	-	+
E-cadherin	-(ILC特征性表现)	+

联合GATA3+CK7+CK20+CDX2鉴别准确率>95%, 但需结合临床病理背景综合判断.

2.4 液体活检

现有研究显示, 循环肿瘤DNA(circulating tumor DNA, ctDNA)可早期预警GIM, 检测敏感度75%-85%, 特异度90%; 循环肿瘤细胞计数与肿瘤转移负荷、患者预后呈负相关; ctDNA甲基化谱可区分肿瘤来源于乳腺或胃肠道, 有望成为无创鉴别诊断的重要手段[36].

3 系统治疗

GIM治疗以全身系统治疗为核心, 化疗应优选胃肠道刺激性低的药物(如口服卡培他滨、长春瑞滨, 或静脉艾立布林等); 原则上不推荐高强度多药联合化疗, 以降低消化道穿孔、出血等风险. 整体方案需严格依据肿瘤分子分型制定个体化策略(表2).

表2 不同分子分型乳腺癌胃肠道转移一线及后线核心治疗药物.

分子分型	一线首选方案	后线核心药物
HR+/HER2-(含HER2低表达)	内分泌治疗+CDK4/6抑制剂	PI3K/AKT抑制剂、化疗、戈沙妥珠单抗
HER2阳性	化疗+抗HER2靶向治疗	德曲妥珠单抗、维迪西妥单抗、恩美曲妥珠单抗
三阴性乳腺癌	化疗±免疫检查点抑制剂(PD-L1阳性)	芦康沙妥珠单抗、戈沙妥珠单抗、PARP抑制剂

PD-L1: 程序性死亡配体-1.

3.1 HR+/HER2-亚型(含HER2低表达)

一线首选内分泌治疗联合CDK4/6抑制剂, 该方案在内脏转移人群中PFS可达12-16 mo[37], 但GIM亚组的前瞻性数据仍有限, 临床应用时需结合患者消化道耐受情况动态调整. 后线治疗若存在AKT突变, 优先选择Capivasertib联合氟维司群; PIK3CA突变者可选用伊那利塞联合哌柏西利及氟维司群(需结合前线治疗史调整); 无明确靶点突变者, 戈沙妥珠单抗是重要的后线选择[35,38,39].

3.2 HER2阳性亚型

核心策略为化疗联合抗HER2靶向治疗. 后线可选择德曲妥珠单抗, 其依据主要来自DESTINY-Breast系列研究, 但其中GIM亚组仅占入组人群的3%-5%, 目前尚缺乏GIM专属Ⅲ期试验数据, 临床应用时需关注间质性肺炎及消化道不良反应风险[40]; 维迪西妥单抗对HER2低表达人群疗效确切, 安全性优势突出[41].

3.3 三阴性乳腺癌

一线推荐常规化疗, PD-L1阳性者可联合免疫检查点抑制剂, 治疗过程中需全程监测免疫相关胃肠炎、消化道溃疡等不良反应, 及时对症干预. 后线可选芦康沙妥珠单抗或戈沙妥珠单抗, 二者疗效证据主要基于总体人群研究, 暂无GIM专属高级别循证支持; 对于携带BRCA1/2突变的患者, 应优先考虑PARP抑制剂[42].

4 局部治疗与外科干预

GIM原则上不推荐根治性外科切除, 手术仅限急症挽救处理[43]. 手术绝对指征: 消化道大出血、穿孔、完全性肠梗阻、消化道重度狭窄导致进食障碍; 相对指征: 孤立病灶姑息减瘤、消化道短路或造口减症; 广泛腹膜转移、终末期恶病质、可通过内镜支架解除梗阻者为手术禁忌. 临床优先选择内镜、介入治疗替代外科手术, 可行消化道支架置入、内镜止血、血管栓塞止血等操作; 姑息放疗多用于食管狭窄、难治性消化道出血及顽固性疼痛, 临床采用低剂量姑息放疗, 总剂量建议≤30 Gy, 单次剂量≤3 Gy, 禁止大剂量放疗, 避免诱发消化道穿孔、出血.

GIM患者常伴随恶病质、癌性疼痛、焦虑抑郁等问题, 建议在全身治疗基础上尽早联合姑息治疗团队参与全程管理. 针对难治性恶心呕吐可选用中枢止吐药联合胃黏膜保护剂; 恶性肠梗阻不建议严格禁食, 推荐采用奥曲肽联合糖皮质激素控制症状, 必要时行胃造瘘或肠外营养支持; 终末期患者以控制症状、维持生活质量为核心, 避免过度医疗.

5 预后因素、现存挑战与未来研究方向

5.1 预后因素与生存分析

未经规范系统治疗的GIM患者中位总生存(overall survival, OS)仅3-6 mo; 接受规范全身治疗后中位OS可提升至18-30 mo. 进入ADC治疗时代, HER2阳性GIM患者2年生存率48%-52%, 三阴性乳腺癌型GIM患者2年生存率38%-45%; HR阳性患者依托内分泌治疗联合CDK4/6抑制剂, 整体预后更优. 不良预后因素: 印戒细胞分化、皮革胃样改变、多脏器转移、合并消化道急症、三阴性分型、误诊延误超3 mo、Ki67高表达、广泛腹膜转移. 良好预后因素: HR阳性表达、单发孤立转移灶、早期确诊、靶向/ADC药物治疗敏感. 上述生存数据来自多项回顾性研究汇总分析[44], 受随访时长、治疗方案差异影响, 仅作临床参考, 临床决策需结合患者个体情况综合判断.

5.2 现存挑战与未满足需求

(1)临床跨科室认知不足, 整体误诊率居高不下; (2)缺少大型Ⅲ期前瞻性临床试验, 现有证据多来源于临床试验亚组及回顾性研究; (3)急症处理标准不统一, 存在过度手术或保守治疗不当的问题; (4)暂无GIM专属疗效预测标志物; (5)靶向、化疗所致胃肠道不良反应及肿瘤继发恶病质、肠梗阻, 缺少标准化防治方案.

5.3 未来研究方向

(1)构建ctDNA甲基化、微小RNA无创鉴别诊断模型; (2)推进多款新型ADC(DatoDXd、HER3DXd、CLDN6ADC)在GIM领域临床试验; (3)靶向 CXCR4/CCR9、Wnt通路, 探索恢复Ecadherin表达的干预手段; (4)探索肠道微生态调控方案, 减轻黏膜损伤、逆转耐药; (5)开展GIM前瞻性注册临床研究; (6)普及乳腺科、消化科、外科、影像科、病理科多学科诊疗(multidisciplinary team, MDT)协作模式[45], 明确各科室职责: 乳腺科主导分子分型评估与全身治疗方案制定, 消化科负责内镜下活检与急症处置, 外科仅参与出血、穿孔、完全梗阻等急症手术, 病理科需在活检后及时完成免疫组化判读, 保障多学科诊疗衔接顺畅; (7)建立靶向药物消化道不良反应规范化管理体系; (8)总结长期生存病例与罕见部位转移临床特征.

6 结论

乳腺癌胃肠道转移多见于浸润性小叶癌, 该病发病隐匿、误诊率高、整体预后较差. 随着分子病理精准鉴别技术、新一代ADC药物在临床普及, GIM治疗已从传统姑息化疗, 转变为分子分型指导下、全身治疗为主、外科手术仅用于急症的个体化综合诊疗模式. 临床工作中, ILC患者新发消化道不适需优先排查胃肠道转移, 确诊依靠内镜活检联合免疫组化检测; 治疗依据分子分型选用ADC、靶向或内分泌药物; 外科手术严格限定于出血、穿孔、完全梗阻等急症; MDT协作是降低误诊率、优化全程管理的关键. 未来仍需开展高质量前瞻性研究, 推动GIM专属诊疗指南制定, 持续改善患者生存与生活质量.

参考文献

1.	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263.  [PubMed]  [DOI]

2.

Thill M, Janni W, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Hörner-Rieber J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reinisch M, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, van Mackelenbergh M, Witzel I, Wöckel A, Würstlein R, Müller V, Park-Simon TW. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025. Breast Care (Basel). 2025;20:208-219.  [PubMed]  [DOI]

3.	Aktas A, Gurleyik MG, Akkus D, Ucur Z, Aker F. Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes. Breast Cancer Res Treat. 2025;212:347-359.  [PubMed]  [DOI]

4.	Peng J, Liu Y, Zhang Y, Yang H, Sun G, Zhu L, Zhao Y. Unmasking hidden metastasis: A case report of gastrointestinal metastasis detected a decade after breast cancer diagnosis. Medicine (Baltimore). 2025;104:e43893.  [PubMed]  [DOI]

5.	Karkeabadi N, Omranipour R, Nozheh A, Farazmand B, Esmaeilian S. Invasive lobular carcinoma of the breast with multifocal gastrointestinal, ovarian, and peritoneal metastases: a case report. J Med Case Rep. 2026;20:194.  [PubMed]  [DOI]

6.	Wehbe S, Firkins SA, Sweeney JR, Moore HCF, Rouphael C. Covert Breast Cancer Metastasis to the Gastrointestinal Tract: Is Extra Vigilance Needed? ACG Case Rep J. 2025;12:e01582.  [PubMed]  [DOI]

7.	Wang S, Li W, Li S, Liu X, Zhang L, Hao C, Meng W, Zhao W, Tong Z. Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients. Int J Surg Pathol. 2023;31:1075-1084.  [PubMed]  [DOI]

8.	Pouptsis A, Cano Gimeno J, Martinez Rubio C, Bañuls Marrades M, Olivan Sasot P. Metastatic Occult Primary Lobular Breast Cancer: A Case Report. Cureus. 2024;16:e58586.  [PubMed]  [DOI]

9.	Sun TT, Liu FG. The analysis about the metastases to Gastrointestinal tract: a literature review, 2000-2023. Front Oncol. 2025;15:1552932.  [PubMed]  [DOI]

10.	Lyu Z, Fei J, Zhang L, Liu Y. Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: a case report and literature review. Front Oncol. 2025;15:1576874.  [PubMed]  [DOI]

11.	Yoo KC, Kim DH, Park S, Yun H, Ryu DH, Lee J, Son SM. Gastric Metastasis Mimicking Early Gastric Cancer from Invasive Ductal Carcinoma of the Breast: Case Report and Literature Review. Medicina (Kaunas). 2024;60:980.  [PubMed]  [DOI]

12.	Zhu L, Li J, Yang L, Li T, Zhang P, Li P, Hong Y. Multiple gastrointestinal metastases in de novo invasive ductal carcinoma of the breast: A case report and literature review. SAGE Open Med Case Rep. 2026;14:2050313X261417159.  [PubMed]  [DOI]

13.	Katuwal B, Morin D, Kolachalam R. Gastrointestinal tract metastasis with subsequent intussusception and obstruction from an invasive lobular breast cancer: a case report. J Surg Case Rep. 2023;2023:rjac623.  [PubMed]  [DOI]

14.	Owaki T, Hashimoto S, Umezu H, Terai S. Delayed and Synchronous Recurrence of Breast Cancer Metastases in Multiple Organs. Intern Med. 2022;61:3355-3359.  [PubMed]  [DOI]

15.	Zengel B, Çavdar D, Özdemir Ö, Taşlı F, Karataş M, Şimşek C, Uslu A. Gastrointestinal Tract Metastases of Invasive Lobular Carcinoma of the Breast: An Immunohistochemical Survey Algorithm. Eur J Breast Health. 2022;18:375-380.  [PubMed]  [DOI]

16.	van Bekkum S, Menke-Pluijmers MBE, Westenend PJ. Gastric metastasis of breast cancer: A frequent mimicker of primary gastric cancer in breast cancer patients. JGH Open. 2022;6:804-808.  [PubMed]  [DOI]

17.	Sun L, Liu J, Guo M, Xu J, Wang D. First diagnosed invasive lobular carcinoma of the breast combined with gastric metastasis and bone metastasis: a case report and review of the literature. BMC Womens Health. 2023;23:133.  [PubMed]  [DOI]

18.	Fousekis FS, Tepelenis K, Stefanou SK, Stefanou CK, Pappas-Gogos G, Theopistos V, Evangelou Z, Mauri D, Christodoulou DK. Gastric metastasis from breast cancer presenting as dysphagia. J Surg Case Rep. 2022;2022:rjac080.  [PubMed]  [DOI]

19.	Namikawa T, Yokota K, Maeda H, Kitagawa H, Tamura M, Satake H, Sugimoto T, Kobayashi M, Hanazaki K, Seo S. Gastric and Bone Metastases Arising from Invasive Lobular Carcinoma With Ductal Carcinoma Occurring in one Breast Synchronously. Anticancer Res. 2023;43:3701-3707.  [PubMed]  [DOI]

20.	Wang BQ, Fang XG, Xiang BH, Wang XJ, Cao M, Zhuang CL, Liu ZC, Wang Z. Metastasizing to the colon from triple-negative breast cancer: A case report and review of literature. World J Gastrointest Oncol. 2025;17:103328.  [PubMed]  [DOI]

21.	Matteucci M, Barone G, Zampino L, Codecà C, Dinuzzi VP, Battista A, Rivolta U, Yen M, Galliano M, Bertoglio CL. Colonic metastasis from breast carcinoma: A case report and systematic review of a rare clinical scenario. Int J Colorectal Dis. 2026;41:61.  [PubMed]  [DOI]

22.	Alsobahi NA, Mohammed TA. Small bowel obstruction as first presentation of metastatic lobular breast cancer for pilgrim patient. Int J Surg Case Rep. 2024;120:109855.  [PubMed]  [DOI]

23.	Radhakrishnan L, Mukherjee R, Singh BK, Maheswari Y, Dharmashaktu Y, Krishna A, Seenu V. Isolated Ileocecal Metastasis from Lobular Carcinoma of the Breast: A Case Report. Eur J Breast Health. 2025;22:102-105.  [PubMed]  [DOI]

24.	Da Cunha T, Restrepo D, Abi-Saleh S, Dharan M. Breast cancer metastasizing to the upper gastrointestinal tract (the esophagus and the stomach): A comprehensive review of the literature. World J Gastrointest Oncol. 2023;15:1332-1341.  [PubMed]  [DOI]

25.	Capelli G, Sala C, Sauta MG, Gerbasi DM, Crisafulli V, Buragina G, Mariani P, Rampinelli LA. Colonic Metastasis of Previously Undetected Invasive Lobular Carcinoma in a 68-Year-Old Woman Undergoing Regular Breast Screening. Cureus. 2025;17:e96816.  [PubMed]  [DOI]

26.	Shin D, Sun H, Mantri N, Patel H. Gastric Metastasis 5 Years after Primary Invasive Lobular Adenocarcinoma of the Breast. Case Rep Gastroenterol. 2023;17:221-227.  [PubMed]  [DOI]

27.	Martín-Quesada AI, Martín-Abreu C. Advances in the management of metastatic lobular breast cancer: Current evidence and emerging treatments. Semin Oncol. 2026;53:152466.  [PubMed]  [DOI]

28.	Kartotaroeno J, Bastid C, Puppa G. Gastric Signet Ring Cell Carcinoma Metastasis From Lobular Breast Cancer: A Diagnostic Pitfall. Cureus. 2024;16:e59919.  [PubMed]  [DOI]

29.	Faraz A, Kowalczyk S, Hendrixson M. Diffuse Gastrointestinal Metastasis From Breast Cancer: A Case Report and Literature Review. Cureus. 2024;16:e63608.  [PubMed]  [DOI]

30.	Watanabe Y, Horimoto Y, Takahashi Y, Murakami F, Yamada M, Yamazaki S, Ishido Y. A Gastric Metastatic Lesion That Resembled Early-Stage Gastric Cancer on Endoscopy during Treatment for Recurrent Breast Cancer: A Case Report. Case Rep Oncol. 2021;14:1719-1724.  [PubMed]  [DOI]

31.	Dilawar H, Ahmed A, Habib S, Iqbal J, Abdul Rehman T, Hadi I, Nisa N, Fatima S. Gastric Metastasis from Invasive Lobular Breast Cancer, Resembling Primary Gastric Cancer. J Nucl Med Technol. 2024;52:68-70.  [PubMed]  [DOI]

32.	Hirano K, Nomura K, Ochiai Y, Hayasaka J, Suzuki Y, Mitsunaga Y, Odagiri H, Masui A, Kikuchi D, Hoteya S. Metastatic Gastric Tumors: Clinical and Endoscopic Features. Cureus. 2024;16:e58678.  [PubMed]  [DOI]

33.	Gandhi C, Chavan R, Patel M, Solanki R, Prajapati M, Bhatt D, Rajput S. Combined endoscopic and laparoscopic anastomosis with lumen-apposing metal stent for treatment of obstructed gastrojejunal anastomotic malignancy. Endoscopy. 2024;56:E536-E537.  [PubMed]  [DOI]

34.	Wang HX, Yin YM, Hu XC. Expert consensus on BRCA1/2 gene testing and clinical application in Chinese breast cancer patients (2025 edition). China Oncol. 2025;35:710-734.  [PubMed]  [DOI]

35.

Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, Li H, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Stout TJ, Hutchinson KE, Schutzman JL, Song C, Jhaveri KL. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024;391:1584-1596.  [PubMed]  [DOI]

36.

Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, Bargiacchi S, Macagno M, Grammatico P, Giannini G, Cortesi E, Di Nicolantonio F, Gazzaniga P. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Lett. 2021;507:89-96.  [PubMed]  [DOI]

37.	Sasaki A, Masuda S, Yoshioka T, Saito A, Motomura Y. Therapeutic Effects of CDK4/6 Inhibitors in Gastric and Colonic Metastases From Breast Cancer: A Case Report. Cureus. 2024;16:e52765.  [PubMed]  [DOI]

38.

Cejalvo Andújar JM, Ayala de la Peña F, Margeli Vila M, Pascual J, Tolosa P, Pages C, Cuenca M, Guerrero Zotano Á. Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression. Cancer Drug Resist. 2025;8:5.  [PubMed]  [DOI]

39.

Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer. 2025;11:34.  [PubMed]  [DOI]

40.

Siena S, Chalabi M, Goodwin R, Osterlund P, Penault-Llorca F, Sartore-Bianchi A, Starling N, Stintzing S, Tabernero J. Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review. Cancer Treat Rev. 2026;144:103097.  [PubMed]  [DOI]

41.	Wu R, Chen X, Li T, Zhang Y, Ling X. Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report. Front Oncol. 2026;16:1652716.  [PubMed]  [DOI]

42.	Zhu L, Xing Y, Wang M. Triple-negative invasive lobular carcinoma presenting with synchronous gastric metastasis: A case report. Oncol Lett. 2025;30:496.  [PubMed]  [DOI]

43.	Ávila L, Branco T, Leandro H, Silva R, Mendes R, Coelho F. Ileocecal Valve Metastasis Inducing Cecal Volvulus in a Patient With Lobular Breast Cancer: A Rare Cause of Bowel Obstruction. Cureus. 2024;16:e73345.  [PubMed]  [DOI]

44.	Bolzacchini E, Nigro O, Inversini D, Giordano M, Maconi G. Intestinal metastasis from breast cancer: Presentation, treatment and survival from a systematic literature review. World J Clin Oncol. 2021;12:382-392.  [PubMed]  [DOI]

45.	赋能专科建设-共创健康中国多学科专家委员会; 集体作者中国抗癌协会乳腺癌专业委员会; 杨 犇龙, 吴 炅. 乳腺癌多学科诊疗标准与规范(2023年版). 中国癌症杂志. 2023;33:1188-1203.  [PubMed]  [DOI]

备注

学科分类: 胃肠病学和肝病学

手稿来源地: 江苏省

同行评议报告学术质量分类

A级 (优秀): 0

B级 (非常好): B

C级 (良好): C, C

D级 (一般): 0

E级 (差): E

科学编辑: 刘继红 制作编辑:张砚梁